Primary bone marrow diffuse large B cell lymphoma: a case series and review

被引：38

作者：

Chang, Hung ^{[1
,2
]}

Hung, Yu-Shin ^{[1
,2
]}

Lin, Tung-Liang ^{[1
,2
]}

Wang, Po-Nan ^{[1
,2
]}

Kuo, Ming-Chung ^{[1
,2
]}

Tang, Tzung-Chih ^{[1
,2
]}

Wu, Jin-Hou ^{[1
,2
]}

Dunn, Po ^{[1
,2
]}

Shih, Lee-Yung ^{[1
,2
]}

机构：

[1] Chang Gung Mem Hosp, Div Hematol Oncol, Taipei 10591, Taiwan

[2] Chang Gung Univ, Sch Med, Tao Yuan, Taiwan

来源：

ANNALS OF HEMATOLOGY | 2011年 / 90卷 / 07期

关键词：

Diffuse large B cell lymphoma; Bone marrow; Rituximab; CD5; CD5(+); INVOLVEMENT;

D O I：

10.1007/s00277-010-1129-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diffuse large cell lymphoma involving bone marrow is not uncommon, but primary, de novo, bone marrow diffuse large B cell lymphoma (DLBCL) is rare. To understand the clinical features and outcomes of this distinct entity, we collected 12 cases in 5 years from a single-center database. They accounted for 1.16% of lymphoma, or 2.65% of diffuse large B cell lymphoma. Nine cases presented with fever of unknown origin. Lactate dehydrogenase levels were elevated in all but one case. Nine cases belonged to the high-risk group according to their international prognosis indexes (score 4 or 5). Four patients received no chemotherapy, all of whom died within 1 month. Four patients received cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP)-like chemotherapy, and their median survival was 13 months. Finally, four patients received rituximab 375 mg/m(2) in addition to CHOP-like chemotherapy. All of them had complete remission and three are still alive without relapse. We concluded that primary bone marrow DLBCL is a rare but distinctive subtype of lymphoma. The prognosis for this entity is poor but rituximab-based treatment is promising for improving its outcomes.

引用

页码：791 / 796

页数：6

共 21 条

[1] Isolated bone marrow involvement in diffuse large B cell lymphoma: A report of three cases with review of morphological, immunophenotypic and cytogenetic findings [J].